RETRACTED ARTICLE: The best drug supplement for obesity treatment: a systematic review and network meta-analysis

Salari, Nader; Jafari, Samira; Darvishi, Niloofar; Valipour, Elahe; Mohammadi, Masoud; Mansouri, Kamran; Shohaimi, Shamarina

doi:10.1186/s13098-021-00733-5

Diabetology & Metabolic Syndrome

Table 1 Information of studies included in the analysis step. mean age, sex and supplement type

From: RETRACTED ARTICLE: The best drug supplement for obesity treatment: a systematic review and network meta-analysis

Row	First author	Publication year	Setting	Mean age		Total patients	Supplement type	Men/women
Row	First author	Publication year	Setting	Intervention	Control	Total patients	Supplement type	Men/women
1	Apovian [25]	2013	America	44.3 ± 11.2	44.4 ± 11.4	1496	Placebo	76/419
1	Apovian [25]	2013	America	44.3 ± 11.2	44.4 ± 11.4	1496	Naltrexone + bupropion	155/846
2	Aronne [26]	2010	America	42 ± 11	42 ± 11	244	Placebo	13/87
2	Aronne [26]	2010	America	42 ± 11	42 ± 11	244	Pramlintide	12/88
3	Davies [27]	2015	France, Germany, Israel, South Africa, Spain, Sweden, Turkey, United Kingdom		57.4 ± 9.8	864	Placebo	97/115
							Liraglutide 0.3 mg	220/203
							Liraglutide 1.8 mg	108/103
4	Fidler [28]	2011	America	BID: 43.8 ± 11.8	43.7 ± 11.8	4004	Placebo	353/1248
				QD: 43.8 ± 11.7			Lorcaserin 10 mg BID	313/1289
				QD: 43.8 ± 11.7			Lorcaserin 10 mg QD	145/656
5	Gadde [29]	2011	America	(7.5 mg + 46 mg): 51.1 ± 10.43	51.2 ± 10.25	2487	Placebo	299/695
				(15 mg + 92 mg): 51.0 ± 10.65			Phentermine 7.5 mg + topiramate 46.0 mg	149/349
				(15 mg + 92 mg): 51.0 ± 10.65			Phentermine 15.0 mg + topiramate 92.0 mg	302/693
6	Greenway [30]	2010	America	16 mg: 44.4 ± 11.3	43.7 ± 11.1	1742	Placebo	85/496
				32 mg: 44.4 ± 11.1			Naltrexone + bupropion 16.0 mg	88/490
				32 mg: 44.4 ± 11.1			Naltrexone + bupropion 32.0 mg	87/496
7	le Roux [31]	2017	America	47.5 ± 11.7	47.3 ± 11.8	2254	Placebo	176/573
7	le Roux [31]	2017	America	47.5 ± 11.7	47.3 ± 11.8	2254	Liraglutide	364/1141
8	Lu [32]	2018	China	34.7 ± 9.0	37.0 ± 10.0	171	Placebo	28/57
8	Lu [32]	2018	China	34.7 ± 9.0	37.0 ± 10.0	171	Lorcaserin	39/46
9	O’neil [33]	2012	America	BID: 53.9 ± 8.1	53.2 ± 8.3	508	Placebo	73/84
				QD: 53.5 ± 7.4			Orlistat 120.0 mg BID	86/83
				QD: 53.5 ± 7.4			Orlistat 120.0 mg QD	34/41
10	Pi-Sunyer [34]	2015	Europe, North America, South America, Asia, Africa, Australia	45.0 ± 12.0	45.2 ± 12.1	3731	Placebo	273/971
10	Pi-Sunyer [34]	2015		45.0 ± 12.0	45.2 ± 12.1	3731	Liraglutide	530/1957
11	Smith [35]	2010	America	43.8 ± 0.3	44.4 ± 0.3	3182	Placebo	253/1331
11	Smith [35]	2010	America	43.8 ± 0.3	44.4 ± 0.3	3182	Lorcaserin	272/1321

Back to article page

ISSN: 1758-5996

Contact us

Submission enquiries: journalsubmissions@springernature.com